Author

Shufen Lim

Observed names: S Lim, S.T.H. Lim, SHUFEN LIM, Shufen T. H. Lim

Institution: Eli Lilly (United States)

Observed institutions: National University of Singapore, Eli Lilly (United States)

OpenAlex ID: A5113737009

Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a)

2023 · Steven E. Nissen, Helle Linnebjerg, et al. · JAMA · 236

Single‐dose pharmacokinetics and glucodynamics of the novel, long‐acting basal insulin LY2605541 in healthy subjects

2014 · Vikram P. Sinha, Siak Leng Choi, et al. · The Journal of Clinical Pharmacology · 47

Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies

2025 · Kausik K. Ray, Helle Linnebjerg, et al. · Journal of the American College of Cardiology · 26

Solbinsiran, a Galnac-conjugated Sirna Targeting Angptl3, Reduces Atherogenic Lipoproteins in Individuals With Mixed Dyslipidaemia in a Durable and Dosedependent Manner

2024 · Kausik Kumar Ray, Giacomo Ruotolo, et al. · Journal of the American College of Cardiology · 14

Ultra-rapid Lispro (URLi) Reduces Postprandial Glucose Excursions vs. Humalog® in Patients with T1D at Multiple Meal-to-Dose Timing Intervals

2018 · LEONA PLUM-MOERSCHEL, JENNIFER LEOHR, et al. · Diabetes · 8

Po423 Single-dose Pharmacokinetics and Glucodynamics of the Novel, Long-acting Basal Insulin Ly2605541 in Healthy Subjects

2014 · E.J. Pratt, V.P. Sinha, et al. · Diabetes Research and Clinical Practice · 2

1036-P: Bioequivalence of Ultra-Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects

2020 · HELLE LINNEBJERG, ELIZABETH S. LABELL, et al. · Diabetes

Ultra Rapid Lispro (URLi) Reduces Postprandial Glucose Excursions vs. Humalog® in Patients with T1D at Multiple Meal-to-Dose Timing Intervals

2019 · L Plum-Mörschel, J Leohr, et al. · Diabetologie und Stoffwechsel

Works count: 8

Citation count: 333

H-index: 5

I10-index: 4